Serine Hydroxymethyltransferase Anchors de Novo Thymidylate Synthesis Pathway to Nuclear Lamina for DNA Synthesis*§

Received for publication, December 13, 2011, and in revised form, January 9, 2012. Published, JBC Papers in Press, January 10, 2012, DOI 10.1074/jbc.M111.333120

Donald D. Anderson, Collynn F. Woeller, En-Pei Chiang, Barry Shane, and Patrick J. Stover

From the Division of Nutritional Sciences and the Graduate Field of Biochemistry, Molecular and Cell Biology, Cornell University, Ithaca, New York 14853, the Department of Food Science and Biotechnology, National Chung Hsing University, Taichung, Taiwan, and the Department of Nutritional Sciences and Toxicology, University of California, Berkeley, California 94720

Background: De novo thymidylate biosynthesis occurs in the nucleus.
Results: This pathway forms a multienzyme complex that is associated with the nuclear lamina and the DNA replication machinery.
Conclusion: De novo thymidylate biosynthesis occurs at the sites of DNA replication and is enriched at sites of replication initiation.
Significance: The compartmentation of thymidylate biosynthesis at the replication fork may permit regulation of dUTP incorporation into DNA.

The de novo thymidylate biosynthetic pathway in mammalian cells translocates to the nucleus for DNA replication and repair and consists of the enzymes serine hydroxymethyltransferase 1 and 2α (SHMT1 and SHMT2α), thymidylate synthase, and dihydrofolate reductase. In this study, we demonstrate that this pathway forms a multienzyme complex that is associated with the nuclear lamina. SHMT1 or SHMT2α is required for co-localization of dihydrofolate reductase, SHMT, and thymidylate synthase to the nuclear lamina, indicating that SHMT serves as a scaffold protein that is essential for complex formation. The metabolic complex is enriched at sites of DNA replication initiation and associated with proliferating cell nuclear antigen and other components of the DNA replication machinery. These data provide a mechanism for previous studies demonstrating that SHMT expression is rate-limiting for de novo thymidylate synthesis and indicate that de novo thymidylate biosynthesis occurs at replication forks.

Regulation of cellular dTTP synthesis is essential for DNA replication and genome stability in the nucleus (1) and mitochondria (2). Depressed de novo thymidylate synthesis resulting from folate deficiency or anti-folate treatment results in deoxyuridine misincorporation into mitochondrial DNA (2) and nuclear DNA leading to genome instability (3). Tetrahydrofolate (THF) is a metabolic cofactor that carries and activates single carbons for the synthesis of purine and thymidine nucleotides and for homocysteine remethylation to methionine (4). Folate-mediated one-carbon metabolism is compartmentalized in the mitochondria, nucleus, and cytoplasm of eukaryotic cells (5). The enzymes that constitute the de novo thymidylate pathway include SHMT1, SHMT2α, thymidylate synthase (TYMS), and dihydrofolate reductase (DHFR). Methylenetetrahydrofolate generated by SHMT is the one-carbon donor for the TYMS-catalyzed conversion of dUMP to thymidylate, generating dihydrofolate. DHFR catalyzes the NADPH-dependent reduction of dihydrofolate to regenerate THF for subsequent cycles of de novo thymidylate synthesis (Fig. 1). SHMT1, TYMS, and DHFR have been localized to the nucleus, and their translocation is mediated by post-translational modification with the small ubiquitin-like modifier (SUMO) (6, 7). SHMT1 nuclear translocation is cell cycle-dependent and occurs during the S and G2/M phases and in response to UV damage (7–9). In mice, nuclear localization of the de novo thymidylate synthesis pathway is required to minimize uracil misincorporation into nuclear DNA (10). Intact purified nuclei from mouse liver exhibit de novo thymidylate synthesis activity, whereas nuclei disrupted by sonication lack this activity, indicating that the formation of a multienzyme complex may be required for the pathway to function (6).

Previous studies in cell culture and mouse models have shown that SHMT1 expression determines de novo thymidylate synthesis activity, indicating that this enzyme is limiting for de novo thymidylate synthesis in vivo (11, 12). In mammals, there are two SHMT isozymes encoded by distinct genes (13–15). SHMT1 encodes the cytoplasmic/nuclear isoform (SHMT1), and SHMT2 encodes the mitochondrial (SHMT2) and the cytoplasmic/nuclear (SHMT2α) isoform through alternative promoter use (6, 13–15). This second SHMT2 transcript encodes SHMT2α, which provides functional redundancy with SHMT1 in the de novo thymidylate synthesis pathway. De novo thymidylate biosynthesis activity is reduced by 75% in nuclei isolated from Shmt1<sup>−/−</sup> mice (6).
Recent evidence indicates that the formation of a multienzyme metabolic complex is required for de novo purine nucleotide biosynthesis in the cytoplasm, referred to as a purinosome (16, 17). Formation of the purinosome is regulated by cell cycle, purine levels, protein kinases (18), microtubule networks (19), and sumoylation (17), with disruption of microtubule networks resulting in the suppression of de novo purine biosynthesis. A nuclear multienzyme complex, termed the replitase, which contained some of the enzyme activities required for the de novo thymidylate cycle, including ribonucleotide reductase, TYMS, and DHFR, as well as DNA polymerase, was identified in mammalian nuclear extracts from S phase cells (20, 21). Other studies have identified SHMT1 as an interacting partner with proliferating cell nuclear antigen (PCNA), indicating that SHMT1 and the de novo thymidylate pathway may localize to sites of DNA synthesis (8, 22). PCNA is a DNA replication and repair processivity factor, which acts as a "sliding clamp" and crucial factor for the localization of proteins to replication forks and repair foci (23, 24).

Shmt1−/+ mice accumulate uracil within nuclear DNA (12) and show increased susceptibility to neural tube defects (25) and intestinal cancer (26). In this study, we investigated the presence of a nuclear multienzyme complex that included SHMT and the entire de novo thymidylate pathway, and its association with the DNA replication machinery. The results of this study demonstrate that the de novo thymidylate synthesis pathway is associated with nuclear lamina and that SHMT1 or SHMT2 serve essential roles as scaffold proteins for complex formation. Furthermore, this metabolic complex is enriched at sites of DNA replication initiation, indicating that de novo thymidine nucleotide synthesis occurs at the sites of DNA synthesis.

**MATERIALS AND METHODS**

**Cell Lines and Culture Medium**—HeLa cells were obtained and cultured as reported previously (6). Cells were cultured in α-MEM or DMEM (Hyclone) supplemented with 10% fetal bovine serum (Hyclone) and penicillin/streptomycin (Mediatech) at 37 °C and 5% CO₂. For all experiments, α-MEM (Hyclone) lacking nucleosides was used and supplemented with 10% dialyzed and charcoal treated fetal bovine serum and penicillin/streptomycin (Mediatech) with and without the four...
SHMT and Nuclear Thymidylate Synthesis

Generation of Human DN2-SHMT1-expressing Cell Lines—Generation of the pet28a-DN2-SHMT1 cDNA was described previously (29). This DN2-SHMT1 cDNA was cloned into the KpnI and BamHI (New England Biolabs) site of the pcDNA4/TO/myc-His C vector (Invitrogen), generating pcDNA4-DN2-SHMT1. Stable SH-SY5Y cell lines expressing pcDNA6/TR vector (Invitrogen) and pcDNA4-DN2-SHMT1 were generated. SH-SY5Y cells were electroporated with 20 µg of plasmid DNA (pcDNA4-DN2-SHMT1 and pcDNA6/TR vector) at 0.22 kV and 950 microfarads (Bio-Rad Gene-Pulser) and 1:1000 protease inhibitor mixture (Sigma) to select for cells that integrated the plasmid. Individual colonies resistant to Zeocin treatment were selected and expanded using α-MEM containing blasticidin (10 µg/ml) and Zeocin (100 µg/ml; Invitrogen) to select for cells that integrated the plasmid. Individual colonies resistant to Zeocin treatment were selected and expanded using α-MEM containing blasticidin and Zeocin, and clonal lines expressing human DN2-SHMT1 protein were screened by Western blot analyses.

Vectors and Transfection Procedures—The pCMV6-AC-DHFR-GFP, pCMV6-AC-TYMS-GFP, phiYFP-SHMT1, and SHMT1 protein were screened by Western blot analyses. Preparation for fluorescence-activated cell sorting (FACS) was described previously (8). FACS analysis was performed at the Biomedical Sciences Flow Cytometry Core Laboratory, Cornell University.

Immunoblotting—SHMT1, SHMT2, TYMS, DHFR, and GAPDH immunoblots were performed as described previously (6,7). Antibodies directed toward PCNA and the SV40 large T antigen were diluted in 5% nonfat dry milk (Carnation) containing 1% Nonidet P-40 (U.S. Biologicals) at a concentration of 1 µg/ml and 1:1000, respectively. Goat antimouse HRP (Pierce) secondary antibodies were used at a dilution of 1:10,000. SuperSignal West Pico Chemiluminescent substrate was used for visualization (Pierce).

Immunoprecipitation—Immunoprecipitation was conducted using the Dynabeads Protein G immunoprecipitation kit (Invitrogen). For whole cell immunoprecipitation, HeLa cells were lysed using mammalian protein extraction reagent (Pierce) supplemented with 2 mm β-mercaptoethanol (Calbiochem), 0.1 mm EDTA (Fisher), 1 mm PMSF (Alexis Biochemicals), and 1:1000 protease inhibitor mixture (Sigma). For immunoprecipitations from nuclear and cytosolic extracts, nuclei were purified using the Active Motif Nuclear extract kit per the manufacturer’s protocol. Antibodies directed toward the following proteins were purchased from Abcam: DNA polymerase δ, uracil DNA glycosylase 2 (UNG2), PCNA, and DHFR. Lamin A/C, Lamin B1, DNA polymerase ε, lysine demethylase 1 (KDM1), and replication factor C activator 1 (RFC1) antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Non-immune IgG was purchased from Pierce. SHMT1 antibody was obtained as described previously (8). 1 mg of total protein per sample was incubated with 5 µg of antibody overnight at 4 °C. The beads were collected and washed four times with PBS, 0.1% Tween 20 (Fisher). For lamin A/C and lamin B1 immunoprecipitations, washes contained either 150 mm NaCl or 650 mm NaCl in PBS, 0.1% Tween 20. For all immunoprecipitations, 40 µl of SDS-PAGE sample buffer were added to the beads to elute the protein with heating at 100 °C.

SHMT1 Tandem Affinity Purification—pNTAPB-SHMT1 was transfected into HeLa cells as described above. For the isolation of TAP-tagged SHMT1 and co-eluting proteins, the Interplay Mammalian TAP System kit (Stratagene) was used following the manufacturer’s protocol. For isolation of FLAG-SHMT1-MAT and co-eluting proteins for peptide sequencing, pCMV-FLAG-SHMT1-MAT-Tag-1 was transfected as described above. Approximately 4 × 10⁸ HeLa cells were used per group. The groups were as follows: empty pCMV-FLAG-MAT-Tag-1 control, pCMV-FLAG-SHMT1-MAT-Tag-1 S phase-synchronized cells, and UV-treated cells. UV treatment was

canonical deoxyribonucleosides, each at a concentration of 10 mg/liter. Cells were maintained at 37 °C and 5% CO₂ for 2 passages over 1 week prior to transfection. The SH-SY5Y human neuroblastoma cell line has been described previously (27). Cells were cultured in α-MEM with 10% dialyzed fetal bovine serum for all experiments. The expression of a dominant negative SHMT1 protein, DN2-SHMT1, was induced in cell lines by the addition of 1 µg/ml tetracycline for a minimum of 4 days prior to experimentation as described previously for SH-SY5Y-FDH cell lines (28).

Confocal Microscopy—Following nucleasection, cells were incubated at 37 °C under 5% CO₂ for 24 h. For visualization of nuclei in cells not transfected with pmKate2-Lamin B1, DRAQ5 (Alexis Biochemicals) was used per the manufacturer’s instructions. Confocal microscopy fluorescence (Leica TCS SP2 system) was used to image all cells at the Cornell Microscope and Imaging Facility.

Cell Cycle Synchronization and Analysis—HeLa cells at 60% confluence were arrested at various cell cycle stages using 30 µm lovastatin (Sigma) (for G₁ phase), 2 mm hydroxyurea (Sigma) (for S phase), or 100 ng/ml nocodazole (Sigma) (for G₂/M phase) following transfection. Preparation for fluorescence-activated cell sorting (FACS) was described previously (8). FACS analysis was performed at the Biomedical Sciences Flow Cytometry Core Laboratory, Cornell University.
accomplished as previously reported (9). 24 h following treatments, cells were washed with 20 ml of PBS, 1 mM PMSF three times. Cells were scraped into 5 ml of PBS, 1 mM PMSF and collected in 50-ml conical tubes (Corning Glass). Cells were pelleted at 1000 rpm for 5 min and suspended in 15 ml of swelling buffer (25 mM HEPES (Fisher), pH 7.8, 1.5 mM MgCl₂ (Fisher), 10 mM KCl (Fisher), 0.1% Nonidet P-40 (U.S. Biologicals), 1.0 mM PMSF (Alexis Biochemicals), 1:100 protease inhibitor (Sigma)) and incubated on ice for 10 min. Cells were homogenized with 25 strokes of a B-type Dounce homogenizer, and cell lysis was verified by trypsin blue (Fisher) exclusion. The homogenate was then filtered (70-μm mesh; BD Bioscience) and centrifuged at 4000 rpm for 5 min to collect nuclei. Nuclei were washed with 2× swelling buffer and pelleted by centrifugation. Nuclei were suspended in 1 ml of ice-cold sodium phosphate (Fisher), pH 8.0, 75 mM NaCl, 1 mM PMSF, 1:100 protease inhibitor for histidine tag isolation (Sigma). MgCl₂ was added to a concentration of 2 mM. Benzonase (Sigma) was added at a concentration of 250 units/ml sample for removal of DNA and incubated for 30 min on ice. Following benzonase treatment, samples were centrifuged at 14,000 rpm for 15 min. The supernatant was collected, and FLAG-SHMT1-MAT and co-eluting proteins were purified using Invitrogen His-TALON magnetic beads. Plates were washed three times with ice-cold PBS, and then washed twice with PBS. 20 ml of ice-cold quenching buffer (100 mM Tris, pH 8.0, 150 mM NaCl) was added per plate, and the cells were incubated for 10 min at 4 °C. Each plate was washed three times with PBS at room temperature. Each plate was treated with a 1% formaldehyde (Fisher) solution in PBS and then incubated at room temperature for 10 min. To quench formaldehyde cross-linking, 3 ml of 1.375 M glycine (Fisher) were added. Plates were washed three times with ice-cold PBS supplemented with 0.5 mM PMSF. Cells were scraped into 5 ml of ice-cold PBS containing 0.5 mM PMSF and centrifuged at 1000 rpm for 5 min at 4 °C. The pelleted cells were resuspended in 10 volumes of swelling buffer and then subjected to Dounce homogenization and centrifugation as reported above. Pelleted nuclei were resuspended in 5 ml of sonication buffer (50 mM Heps, pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 0.5 mM PMSF, and 1:1000 protease inhibitor mixture). Nuclei were sonicated using a 3-mm microtip probe on a Branson Sonifier 150 at 80% with 10-s pulses, 10 times, with 1-min incubations on ice between pulses. Sonicated nuclei were centrifuged at 14,000 rpm for 15 min at 4 °C, and the supernatant was supplemented with 1 μg/ml sonicated salmon sperm DNA (Invitrogen) and bovine serum albumin (Sigma) at 1 mg/ml. The lysate was precleared using 50 μl of In Vitrogen Protein G Dynabeads for 2 h at 4 °C, beads were collected on a magnet, and the supernatant was removed. Samples were divided into 1-ml aliquots for immunoprecipitation. 5 μg of PCNA (Abcam) antibody was incubated for 12 h per 1-ml aliquot at 4 °C. 50 μl of In Vitrogen Protein G Dynabeads were added, and the solution was incubated for 1 h at 4 °C. The beads were collected with a magnet and washed twice with 1 ml of sonication buffer. The beads were washed twice with 1 ml of sonication buffer containing 500 mM NaCl and then twice with 1 ml of a solution containing 20 mM Tris, pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.5 mM PMSF, and protease inhibitor mixture. Two more washes were performed with 1 ml of TE buffer. 50 μl of 10 mM DTT was then added to the beads, which were then incubated at 37 °C for 30 min. The eluate was removed, and this step was repeated. The eluates were then combined and diluted 40× with sonication buffer. 10% of the sample was kept for input. The sample was then aliquoted into 1-ml fractions for TYMS, DHFR, SHMT1, and IgG control immunoprecipitations. 5 μg of each antibody was estimated false discovery rate of ~1%, using a reverse decoy database strategy. Gene ontology term enrichment was performed using DAVID with the total set of proteins with a peptide count of ≥3 and a ratio of experimental group peptide counts to control group peptide counts of ≥1 (30, 31).

**Metabolic Isotope Tracer Studies—**Metabolic isotope tracer studies were completed as described previously (32).

**Tandem Chromatin Immunoprecipitation—**Clones 1, 2, and 3 of pBABE-Puro-SV40 LT-expressing HeLa cells that selected using puromycin were used for this experiment. Approximately 2 × 10⁶ cells were used per lane. Each plate was washed three times with ice-cold PBS. The bifunctional cross-linker dimethyl 3,3′-dithiobispropionimidate (Pierce) was suspended at a concentration of 5 mM in PBS at pH 8.0, and 20 ml per plate was added. Cells were incubated at 4 °C for 30 min and then washed twice with PBS. 20 ml of ice-cold quenching buffer (100 mM Tris, pH 8.0, 150 mM NaCl) was added per plate, and the cells were incubated for 10 min at 4 °C. Each plate was washed three times with PBS at room temperature. Each plate was treated with a 1% formaldehyde (Fisher) solution in PBS and then incubated at room temperature for 10 min. To quench formaldehyde cross-linking, 3 ml of 1.375 M glycine (Fisher) were added. Plates were washed three times with ice-cold PBS supplemented with 0.5 mM PMSF. Cells were scraped into 5 ml of ice-cold PBS containing 0.5 mM PMSF and centrifuged at 1000 rpm for 5 min at 4 °C. The pelleted cells were resuspended in 10 volumes of swelling buffer and then subjected to Dounce homogenization and centrifugation as reported above. Pelleted nuclei were resuspended in 5 ml of sonication buffer (50 mM Heps, pH 7.9, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS, 0.5 mM PMSF, and 1:1000 protease inhibitor mixture). Nuclei were sonicated using a 3-mm microtip probe on a Branson Sonifier 150 at 80% with 10-s pulses, 10 times, with 1-min incubations on ice between pulses. Sonicated nuclei were centrifuged at 14,000 rpm for 15 min at 4 °C, and the supernatant was supplemented with 1 μg/ml sonicated salmon sperm DNA (Invitrogen) and bovine serum albumin (Sigma) at 1 mg/ml.

**Mass Spectrometry—**Tandem affinity-purified samples from S phase-blocked and UV-treated cells were run on a 12% polyacrylamide gel and were stained with Novex colloidal blue staining reagent (Invitrogen). The lanes were excised and cut into nine fractions of ~7 mm by 3-mm areas and sent to the Harvard Microchemistry Facility for peptide digestion, purification, and sequencing. Each excised fraction was reduced, carboxamidomethylated, and digested with trypsin. Peptide identification of each digestion mixture was performed by microcapillary reversed-phase HPLC nanoelectrospray tandem mass spectrometry on an LTQ-Orbitrap Velos or XL mass spectrometer (Thermo Fisher Scientific, San Jose, CA). The Orbitrap repetitively surveyed an m/z range from 395 to 1600, whereas data-dependent MS/MS spectra on the 20 (Velos) or 10 (XL) most abundant ions in each survey scan were acquired in the linear ion trap. MS/MS spectra were acquired with relative collision energy of 30%, 2.5-Da isolation width, and recurring ions were dynamically excluded for 60 s. Preliminary sequencing of peptides was facilitated with the SEQUEST algorithm with a 30 ppm mass tolerance against a species-specific (human) subset of the UniProt Knowledgebase. With a custom version of the Harvard Proteomics Browser Suite (Thermo Fisher Scientific), peptide spectrum matches were accepted with mass error of <2.5 ppm and score thresholds to attain an
SHMT and Nuclear Thymidylate Synthesis

Results

SHMT1, SHMT2α, DHFR, and TYMS Are Present in Nuclei during S and G2/M Phases—SHMT1, SHMT2α, TYMS, and DHFR have been localized previously to the nucleus and cytoplasm of human and mouse cell lines (6, 8, 10). Nuclear localization of SHMT1 and SHMT2α in mouse embryonic fibroblasts and human cell lines (6, 8) is restricted to the S and G2/M phases of the cell cycle and in response to UV damage (9). In this study, the nuclear localization of TYMS and DHFR was determined as a function of cell cycle. As seen previously for SHMT1, DHFR (supplemental Fig. S1) and TYMS (supplemental Fig. S2) localized to the nucleus during S and G2/M phases but not in G1 phase. These data confirm that all of the enzymes necessary for de novo thymidylate biosynthesis are present within the nucleus during S and G2/M phases during DNA replication and repair but are restricted to the cytoplasm in G1.

Identification of SHMT1-interacting Proteins in Nuclear Extracts—Intact purified nuclei from mouse liver can convert tritium-labeled serine and dUMP to tritium-labeled thymidylate, but this activity is lost in sonicated nuclei, indicating that nuclear integrity and multienzyme complex formation may be necessary for de novo thymidylate synthesis (6). To determine if the de novo thymidylate biosynthesis pathway is present in nuclei within a multienzyme complex, SHMT1 tandem affinity purification and SHMT1 co-precipitation experiments were performed on benzonase-treated nuclear extracts isolated from S phase cells and cells treated with UV (supplemental Fig. S3). Over 833 proteins were identified as SHMT1-interacting proteins. The list was refined by excluding proteins with fewer than three peptides identified, and the remaining proteins were grouped by gene ontology term enrichment using the bioinformatics tool DAVID (Table 1 and supplemental Tables S1–S5). Multiple proteins involved in nucleotide metabolism and DNA replication and repair were identified, as well as 80 lamin-interacting proteins. The majority of the identified proteins known to be involved in DNA replication and repair, as well as lamin-interacting proteins, were found in both S phase and UV-treated samples, although some of these interactions were identified only in one of those two exposures (Table 1).

Validation of SHMT1-interacting Partners—DNA replication occurs on nucleoskeletal structures (34) and disruption of the nuclear lamina results in DNA replication arrests (35, 36). Several proteins involved in DNA replication are lamin-binding proteins, including PCNA, which acts as a processivity factor for DNA replication (37). SHMT1 has been identified previously as a PCNA-interacting partner (8), and

<table>
<thead>
<tr>
<th>Function</th>
<th>Protein Identification</th>
<th>S-phase</th>
<th>UV</th>
<th>Both</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA repair and replication</td>
<td>APEX1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>LIG3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>LIG4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MNA1T</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>NTHL1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PCNA</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>POLE2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>POLE</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PRIM1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PRIM2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>RFC1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>XAB2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell cycle</td>
<td>RAD21</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>SKP1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>ANAPC5</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ATR</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>CDC27</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>CUL1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CCNB1</td>
<td></td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>CCNH</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>CDK4</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>ATM</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>STAG1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>YWHHAB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamin Binding Proteins</td>
<td>LMNA</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>LMB11</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>LMB2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>DNAJ2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>BAT11</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>IM07</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>LIMA1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>MED10</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>MED14</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>MED19</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>MED22</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>MED4</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

A complete listing of proteins identified is available in supplemental Tables S1–S5.
this interaction was confirmed in this tandem affinity purification experiment (supplemental Fig. S3 and Table 1). To validate SHMT1 as a lamin-interacting partner, co-immunoprecipitation experiments using benzonase-treated nuclear extracts were performed with antibodies against either lamin A/C or lamin B1. SHMT1 co-precipitated with lamin A/C and lamin B1 antibodies under stringent (650 mM NaCl) and less stringent conditions (150 mM NaCl) (Fig. 2A). Neither TYMS nor DHFR co-precipitated with lamin proteins under these conditions.

Other SHMT1-interacting partners identified in Table 1 were validated by co-immunoprecipitation followed by immunoblotting against the interacting protein. SHMT1, TYMS, and DHFR all co-precipitated with PCNA in nuclear extracts (supplemental Fig. S4, A–C) but not in cytoplasmic extracts (supplemental Fig. S4, A and B). Lysine demethylase 1 (KDM1), which has been recently identified as a folate-binding protein (38), immunoprecipitated with anti-SHMT1 antibodies (supplemental Fig. S4D). Other proteins involved in DNA replication and repair, including DNA polymerases δ and ε (POLD and POLE respectively), replication factor C activator 1 (RFC1), and uracil DNA glycosylase 2 (UNG2) (supplemental Fig. S4E) co-immunoprecipitated with SHMT1. In total, eight validations were performed, and no false positives were identified.

**SHMT1 Interaction with TYMS and DHFR Is DNA-dependent**—Neither TYMS nor DHFR were identified as SHMT1- or lamin-interacting proteins by tandem affinity purification. The ability of nuclear SHMT1 to interact with TYMS and DHFR in the absence of DNA digestion was determined by co-precipitation with SHMT1 in small scale tandem affinity purification (Fig. 2B) and SHMT1 immunoprecipitation (Fig. 2C). In the tandem affinity purification, both TYMS and DHFR co-precipitated with SHMT1 in the absence of benzonase treatment (Fig. 2B). However, neither TYMS nor DHFR co-precipitated with SHMT1 in nuclear extracts treated with benzonase, whereas in the absence of benzonase treatment, co-immunoprecipitates contained TYMS and DHFR (Fig. 2C).

**Co-localization of de Novo Thymidylate Biosynthesis Pathway with Lamin B1**—The co-localization of the de novo thymidylate biosynthesis pathway with the nuclear lamina was investigated by confocal microscopy. HeLa cells transfected with pCMV6-AC-DHFR-GFP, phiYFP-N-SHMT1, and mKate-lamin B1 expression plasmids exhibited co-localization of lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear structures and clusters in the S and G2/M phases of the cell cycle (Fig. 2D). To control for potential artifacts resulting from lamin B1 fusion protein expression, confocal microscopy was performed on HeLa cells following transfection of pCMV6-AC-DHFR-GFP, phiYFP-N-SHMT1, and mKate-lamin B1 expression plasmids exhibiting co-localization of lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear structures and clusters in the S and G2/M phases of the cell cycle (Fig. 2D). To control for potential artifacts resulting from lamin B1 fusion protein expression, confocal microscopy was performed on HeLa cells following transfection of pCMV6-AC-DHFR-GFP, phiYFP-N-SHMT1, and mKate-lamin B1 expression plasmids exhibiting co-localization of lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear structures and clusters in the S and G2/M phases of the cell cycle (Fig. 2D). To control for potential artifacts resulting from lamin B1 fusion protein expression, confocal microscopy was performed on HeLa cells following transfection of pCMV6-AC-DHFR-GFP, phiYFP-N-SHMT1, and mKate-lamin B1 expression plasmids exhibiting co-localization of lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear structures and clusters in the S and G2/M phases of the cell cycle (Fig. 2D). To control for potential artifacts resulting from lamin B1 fusion protein expression, confocal microscopy was performed on HeLa cells following transfection of pCMV6-AC-DHFR-GFP, phiYFP-N-SHMT1, and mKate-lamin B1 expression plasmids exhibiting co-localization of lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear structures and clusters in the S and G2/M phases of the cell cycle (Fig. 2D). To control for potential artifacts resulting from lamin B1 fusion protein expression, confocal microscopy was performed on HeLa cells following transfection of pCMV6-AC-DHFR-GFP, phiYFP-N-SHMT1, and mKate-lamin B1 expression plasmids exhibiting co-localization of lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear structures and clusters in the S and G2/M phases of the cell cycle (Fig. 2D). To control for potential artifacts resulting from lamin B1 fusion protein expression, confocal microscopy was performed on HeLa cells following transfection of pCMV6-AC-DHFR-GFP, phiYFP-N-SHMT1, and mKate-lamin B1 expression plasmids exhibiting co-localization of lamin B1, SHMT1, and DHFR fusion proteins in filament-like linear structures and clusters in the S and G2/M phases of the cell cycle (Fig. 2D). To control for potential artifacts resulting from lamin B1 fusion protein expression, confocal microscopy was performed on HeLa cells following transfection of pCMV6-
AC-DHFR-GFP (supplemental Fig. S5A), pCMV6-AC-TYMS-GFP (supplemental Fig. S5, B and C), or phiYFP-N-SHMT1 (supplemental Fig. S5C) plasmids. All three fusion proteins that constitute the de novo thymidylate biosynthesis cycle co-localized as linear structures within nuclei, demonstrating that the formation of these structures was not the result of lamin B1 overexpression.

**Formation of Thymidylate Biosynthesis Complex Is Nucleotide-independent**—Previous studies have demonstrated that the assembly of the purinosome, a cytoplasmic multienzyme complex comprising the de novo purine biosynthesis enzymes, is regulated by purine levels within the cell. The effect of nucleosides on the formation of the de novo thymidylate biosynthesis pathway complex in nuclei was determined in HeLa cells cultured in medium lacking all nucleosides (DMEM), lacking only deoxyuridine (dU), lacking only thymidine (dT), or replete with all nucleosides (α-MEM) following transfection with the plasmids pCMV6-AC-TYMS-GFP, phiYFP-N-SHMT1, and mKate2-lamin B1 (Fig. 3). The presence or absence of nucleosides in the culture media did not affect the co-localization of SHMT1, TYMS, and lamin B1 as determined by confocal microscopy, demonstrating that formation of the observed linear structures is independent of nucleoside availability.

**SHMT1 and SHMT2α Are Required for DHFR, TYMS, and Lamin B1 Co-localization**—The lamin-binding property of SHMT1 and the lack of interactions among TYMS and DHFR and lamins suggested that SHMT1 and/or SHMT2α may function as scaffold proteins required for DHFR and TYMS localization to the lamina and assembly of the de novo thymidylate synthesis pathway complex. Therefore, the co-localization of TYMS and DHFR with nuclear lamins was investigated in the absence of SHMT. DHFR-GFP and mKate-lamin B1 (supplemental Fig. S6A) or TYMS-GFP and mKate-lamin B1 (Fig. 4A) co-localized in HeLa cells transfected with scrambled siRNA in 95% of the observed cells, but co-localization was reduced to 50 and 75%, respectively, in cells treated with SHMT2 siRNA. Lamin B1 and DHFR or TYMS co-localizing structures were observed in only 5 and 14%, respectively, of cells treated with SHMT1 siRNA and were absent in SHMT1 and SHMT2 siRNA-treated samples. Immunoblotting was performed against SHMT1 and SHMT2 to ensure that the knockdown of those enzymes had occurred (Fig. 4B and supplemental Fig. S6B). These data demonstrate that SHMT1 and SHMT2α function as scaffolds that are required for TYMS and DHFR co-localization with lamin B1.

**TYMS, DHFR, and SHMT2 Do Not Affect SHMT1 and Lamin B1 Co-localization**—The effect of TYMS, DHFR, and SHMT2 expression on SHMT1 co-localization with lamin B1 was investigated in HeLa cells expressing SHMT1-YFP and mKate-lamin B1 (supplemental Fig. S7A). Lamin B1 and SHMT1 co-localized independent of reduced TYMS, DHFR, or SHMT2 expression, which was achieved by siRNA treatment. Immunoblotting was performed against TYMS, DHFR, and SHMT2 to ensure that the knockdown of those enzymes had occurred (supplemental Fig. S7B). These data demonstrate that SHMT1 is essential for the de

![FIGURE 3. SHMT1 and TYMS form linear lamin B1 co-localizing structures independent of nucleoside availability.](image-url)
novo thymidylate synthesis pathway complex formation and that SHMT1 anchors the de novo thymidylate pathway to lamin B1.

**SHMT2α Functions as Scaffold Protein Independent of SHMT1**—Previous studies have demonstrated that SHMT1 and SHMT2 are functionally redundant in nuclear de novo thymidylate synthesis (6). The dependence of the SHMT2α-lamin interaction on SHMT1, TYMS, and DHFR expression was investigated in HeLa cells expressing SHMT2α-RFP and mKate-lamin B1 fusion proteins (supplemental Fig. S8A). SHMT2α and lamin B1 co-localized independent of TYMS, DHFR, and SHMT1 expression. Immunoblotting was performed against TYMS, DHFR, and SHMT1 to ensure that the knockdown of those enzymes had occurred (supplemental Fig. S8B). These data demonstrate that SHMT2α co-localizes with

---

**FIGURE 4. SHMT1 and SHMT2 are required for TYMS and lamin B1 co-localization.** A, cDNAs encoding GFP-TYMS, mKate-lamin B1 fusion proteins, and siRNAs, including scrambled (MOCK), SHMT1, SHMT2, or both SHMT1 and SHMT2, were transfected into HeLa cells. Cells were blocked in S phase using hydroxyurea (2 mM) and visualized with confocal microscopy. For each siRNA treatment, 100 cells were counted. The presence of DHFR and lamin B1 co-localizing structures occurred in 95 ± 4, 14 ± 4.5, 75 ± 5.7, and 0 ± 0.6% of cells transfected with scrambled, SHMT1, SHMT2, and both SHMT1 and SHMT2 siRNAs, respectively. Error is expressed in S.D. (n = 3). B, immunoblotting was performed on siRNA-treated samples to ensure knockdown of SHMT1 and SHMT2. GAPDH was visualized as a loading control.
lamin B1 even in the absence of SHMT1, further supporting the functional redundancy of SHMT2a and SHMT1 in nuclear de novo thymidylate synthesis.

**SHMT1 Scaffold Function Can Determine de Novo Thymidylate Synthesis Capacity**—Previous studies of SHMT1-deficient mice (12) and cell culture models (11, 32) have demonstrated strong correlations between SHMT expression and de novo thymidylate synthesis capacity, although enzyme kinetic studies do not indicate that SHMT1 is catalytically rate-limiting in the de novo thymidylate biosynthesis pathway (39). To distinguish between the catalytic and scaffold functions of SHMT1 in nuclear de novo thymidylate biosynthesis, the effect of expressing a dominant negative SHMT1 protein in SH-SY5Y cells that express endogenous SHMT1 on de novo thymidylate synthesis was determined. SHMT is a tetramer, best described as a dimer of obligate dimers, in which amino acid residues from each monomer in the obligate dimer contribute to both active sites in the dimer (29, 40). Previously, we have described the generation of a dominant negative SHMT1 protein, termed DN2-SHMT1(Y82A/Y83F/K257Q), that dimerizes with wild type SHMT1, creating a stable protein that lacks catalytic activity in both active sites of the dimer (29). Tyr-82 is required for hydrophobic stacking with the p-aminobenzoylglutamate moiety of tetrahydrofolate, and the Y82A mutation eliminates folate binding. The side chains of Tyr-83 and Lys-257 are required for SHMT1 catalytic activity. Expression of DN2-SHMT1 in cells expressing endogenous SHMT1 results in the formation of inactive SHMT1 tetramers and a decrease in the specific activity of SHMT1 in the cell. Co-expression of YFP-DN2-SHMT1 and mKate-lamin B fusion proteins resulted in the formation of SHMT1-lamin B linear structures that were indistinguishable from structures resulting from coexpression of wild-type YFP-SHMT1 and mKATE-lamin B (Fig. 5A), indicating that the mutations in DN2-SHMT1 did not impair lamin binding activity.

To determine the effect of DN2-SHMT1 expression on SHMT1 activity in cells with respect to de novo thymidine biosynthesis and homocysteine remethylation, metabolic isotope tracer experiments were performed using L-[2H3]serine and SH-SY5Y cells that express DN2-SHMT1 from a tet-inducible promoter (28). In this assay, the methylene-THF that is generated by SHMT from L-[3H3]serine is incorporated into methionine or thymidine in DNA and on serine and methionine in cellular protein pools was determined by the detection of labeled Met and dehydroalanine (DHA). Dehydroalanine is formed from serine during the derivatization procedure. Enrichment of L-[3,3,3,3-2H3]serine in thymidine (dT) was determined by analysis of nuclear DNA. All values are expressed as the percentage of L-[2,3,3,3-2H3]serine-derived carbons that contain two deuterium atoms (CD2) in the target compound (the ratio of carbons containing two deuterium atoms in the target compound divided by the total number of carbons that contain one or two deuterium atoms × 100). Two independent experiments were performed with duplicate measurements for each sample, and identical values were obtained within each experiment. The results from one experiment are shown. The data demonstrate that tet-inducible expression of DN2-SHMT1 decreased SHMT1 specific activity in homocysteine remethylation to methionine in the cytoplasm by 60%, whereas DN2-SHMT1 expression enhances SHMT1 specific activity in de novo thymidylate biosynthesis by 45%. C, immunoblotting was performed on SH-SY5Y-DN2-SHMT1 cells in a tet-inducible system. The SH-SY5Y-DN2-SHMT1 cells exhibited increased levels of total SHMT1 in response to tetracycline. These cells were used for isotopic tracer studies. GAPDH was used as a loading control.

L-[2H3]serine for 8 days. Fig. 5B shows that 81.3–86.6% of the isotopically labeled serine used for protein synthesis was metabolized because it retained both deuteriums on the C3 carbon in SH-SY5Y cells and SH-SY5Y-DN2-SHMT1 cells in the presence and absence of tetracycline. If the methionine and thymidylate one-carbon units were only derived from SHMT1, the mass +2 species of these metabolites should be ~80% of the labeled species. Expression of DN2-SHMT1 suppressed CD2 incorporation into methionine by 60%, consistent with a loss of
SHMT and Nuclear Thymidylate Synthesis

The highest occupancy was observed around the SV40 origin. The SV40 origin of replication is a critical region for replication initiation. Phosphorylation of PCNA is required for replication fork progression, and PCNA is recruited to the origin by RFC, which interacts with it to form a complex that is required for replication fork progression. RFC also interacts with DNA polymerase and other replication factors, allowing for the processive synthesis and elongation of the replication fork.

The nuclear lamina plays an important role in tethering DNA to the nuclear periphery during replication. Previous studies have shown that the nuclear lamina is required for the initiation of replication at the SV40 origin, and that SHMT1 and SHMT2 anchor the de novo thymidylate synthesis metabolic complex to the nuclear lamina. The identification of SHMT1 and SHMT2 as lamin-binding proteins suggests a key role in tethering DNA to the nuclear lamina and maintaining nuclear structure during replication.

**DISCUSSION**

This study demonstrates that the de novo thymidylate synthesis pathway is present in the nucleus as a metabolic complex associated with the nuclear lamina and that SHMT1 and SHMT2 anchor the de novo thymidylate synthesis metabolic complex to the nuclear lamina. Previous studies have shown that de novo thymidylate synthesis activity in isolated nuclei is impaired following sonication, indicating a role for nuclear architecture in thymidylate synthesis (6). The results of this study provide a mechanism for this observation by demonstrating that SHMT1 and SHMT2 are lamin-binding proteins that serve as scaffold proteins that are essential for assembly of the de novo thymidylate synthesis pathway into a multienzyme complex in the nucleus.

The SHMT1 scaffold function probably accounts for its role as a limiting factor for de novo thymidylate biosynthesis in cell culture and mouse models (11, 12, 32). Uracil levels in nuclear DNA, which are a proxy for thymidylate synthesis capacity, are elevated in Shmt1−/− mice compared with wild-type littermates (12), demonstrating a key role of this enzyme in determining thymidylate synthesis capacity in vivo. The results from this study indicate that the scaffold function of SHMT may be a more important determinant of de novo thymidylate biosynthesis capacity than its catalytic activity. Expression of a dominant negative SHMT1 that lacked catalytic activity but retained lamin binding activity in neuroblastoma reduced the incorporation of SHMT1-derived one-carbon units into methionine synthesis, which occurs in the cytoplasm, but enhanced the incorporation of SHMT1-derived one-carbon units into de novo thymidylate synthesis, which occurs in the nucleus. Furthermore, the identification of MTHFD1 as a component of the nuclear thymidylate biosynthesis complex indicates that formate may be an important source of nuclear methylene-THF for de novo thymidylate biosynthesis.

These data also support a role for de novo thymidylate biosynthesis at the sites of nuclear DNA synthesis. TYMS and DHFR, like SHMT1, were shown to be present in the nucleus only during S and G2/M phases and thereby enable nuclear de novo thymidylate synthesis during DNA replication and repair. The nuclear lamina has been observed to play an important role in tethering DNA to the nuclear periphery during replication.
and repair, and in this study, it is shown to support the formation of the de novo thymidylate synthesis multienzyme complex. The results of this study also indicate that de novo thymidylate biosynthesis occurs at the sites of DNA synthesis and is associated with the DNA replication machinery. SHMT1 was shown to interact with PCNA, RFC1, and the DNA polymerases δ and ε, and PCNA was shown to interact with SHMT1, TYMS, and DHFR. SHMT1, TYMS, and DHFR proteins are associated with replicating DNA and are enriched at sites of DNA replication initiation.

Thymidine nucleotides are unique from the other nucleotides required for DNA replication. They are not essential during DNA replication, because dUTP can be incorporated into DNA in lieu of dTTP. Furthermore, although all other nucleotide synthesis occurs in the cytoplasm, we have shown that the de novo thymidylate biosynthesis pathway localizes to the nucleus and that its presence in the nucleus is essential to prevent uracil accumulation in nuclear DNA (10). The finding that SHMT1 is an essential scaffold for the formation of the de novo thymidylate biosynthesis multicomplex accounts for the sensitivity of Shmt<sup>−/−</sup> mice to increased uracil misincorporation in DNA, increased risk of intestinal cancer (26), and neural tube defects (25). Furthermore, the nuclear compartmentation of de novo thymidylate biosynthesis at the replication fork may permit the regulation of dUTP incorporation into DNA, as opposed to its misincorporation in DNA, for the regulation of transcriptional networks and biological pathways, as has been demonstrated in Drosophila (33, 43).

REFERENCES
tramer. J. Biol. Chem. 278, 10142–10149
Serine Hydroxymethyltransferase Anchors de Novo Thymidylate Synthesis Pathway to Nuclear Lamina for DNA Synthesis
Donald D. Anderson, Collynn F. Woeller, En-Pei Chiang, Barry Shane and Patrick J. Stover

doi: 10.1074/jbc.M111.333120 originally published online January 10, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M111.333120

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2012/01/10/M111.333120.DC1

This article cites 43 references, 26 of which can be accessed free at http://www.jbc.org/content/287/10/7051.full.html#ref-list-1